Aligos Therapeutics, Inc. (ALGS) Presents at Jefferies London Healthcare Conference 2025 Transcript

Yuxi Dong
Jefferies LLC, Analysis Division

All proper. Let’s get began, and good afternoon, everybody. Thanks for becoming a member of us for Jefferies London Healthcare Convention. My identify is Clara Dong, one of many biotech analysts right here at Jefferies. So it is my absolute pleasure to welcome Dr. Lawrence Blatt, CEO of Aligos Therapeutics, to offer us a presentation right here. Welcome.

Lawrence Blatt
CEO, President & Chairman of the Board

Thanks, and thanks to the Jefferies crew for inviting us to current as we speak. I’ll stroll by means of our portfolio at Aligos as we speak. And whereas doing that, I am going to make some forward-looking statements. So we have now a big Section II pipeline at Aligos. Our lead program is in hepatitis B. The molecule is named pevifoscorvir. We name it pevi. Beforehand, you might need heard of ALG-184. I am going to discuss quite a bit about that molecule as we speak. Along with that, we have now a drug — purpose-built beta thyroid agonist, ALG-009. That is accomplished Section IIa testing. I am going to discuss a little bit bit concerning the outcomes there in addition to some preclinical outcomes we have now in weight problems.

We — along with these molecules, we have now a protease inhibitor for coronavirus. It is a pan-coronavirus protease inhibitor. And proper now, right here within the U.Okay., it is present process a Section II examine that is being funded by the MRC. Along with that, in our preclinical portfolio, we have now an antisense oligonucleotide concentrating on hepatitis B virus in addition to an antisense oligonucleotide concentrating on hepatitis delta virus. So I’ll dig deeper into persistent HBV an infection. I believe most individuals know that HBV is the most important persistent viral an infection on the planet that causes